Alpine Immune Sciences Inc (ALPN) Stock Price and Analyst Predictions

The stock has a 36-month beta value of 1.17. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”

The public float for ALPN is 47.05M, and at present, short sellers hold a 11.93% of that float. On April 04, 2024, the average trading volume of ALPN was 1.14M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

ALPN) stock’s latest price update

Alpine Immune Sciences Inc (NASDAQ: ALPN) has seen a decline in its stock price by -2.81 in relation to its previous close of 39.21. However, the company has experienced a 1.76% gain in its stock price over the last five trading sessions. Business Wire reported 2024-03-20 that SEATTLE–(BUSINESS WIRE)–Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference. Thursday, March 28th, Remy Durand, Ph.D., Chief Business Officer at Alpine, will participate in a fireside chat at 3:00 pm ET/12:00 pm PT and the Company.

ALPN’s Market Performance

ALPN’s stock has risen by 1.76% in the past week, with a monthly rise of 3.96% and a quarterly rise of 100.58%. The volatility ratio for the week is 7.62% while the volatility levels for the last 30 days are 6.42% for Alpine Immune Sciences Inc The simple moving average for the past 20 days is 0.43% for ALPN’s stock, with a 108.76% simple moving average for the past 200 days.

Analysts’ Opinion of ALPN

Many brokerage firms have already submitted their reports for ALPN stocks, with Wolfe Research repeating the rating for ALPN by listing it as a “Outperform.” The predicted price for ALPN in the upcoming period, according to Wolfe Research is $44 based on the research report published on February 15, 2024 of the current year 2024.

Berenberg, on the other hand, stated in their research note that they expect to see ALPN reach a price target of $18. The rating they have provided for ALPN stocks is “Buy” according to the report published on October 18th, 2023.

Berenberg gave a rating of “Buy” to ALPN, setting the target price at $18 in the report published on October 17th of the previous year.

ALPN Trading at 17.10% from the 50-Day Moving Average

After a stumble in the market that brought ALPN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.12% of loss for the given period.

Volatility was left at 6.42%, however, over the last 30 days, the volatility rate increased by 7.62%, as shares surge +1.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +91.89% upper at present.

During the last 5 trading sessions, ALPN rose by +1.76%, which changed the moving average for the period of 200-days by +249.63% in comparison to the 20-day moving average, which settled at $37.98. In addition, Alpine Immune Sciences Inc saw 99.95% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ALPN starting from Rickey James Paul, who sale 117,764 shares at the price of $23.32 back on Jan 26 ’24. After this action, Rickey James Paul now owns 0 shares of Alpine Immune Sciences Inc, valued at $2,745,830 using the latest closing price.

Rickey James Paul, the of Alpine Immune Sciences Inc, sale 236 shares at $22.00 during a trade that took place back on Jan 25 ’24, which means that Rickey James Paul is holding 0 shares at $5,192 based on the most recent closing price.

Stock Fundamentals for ALPN

Current profitability levels for the company are sitting at:

  • -0.75 for the present operating margin
  • 0.99 for the gross margin

The net margin for Alpine Immune Sciences Inc stands at -0.51. The total capital return value is set at -0.13. Equity return is now at value -12.69, with -9.63 for asset returns.

Based on Alpine Immune Sciences Inc (ALPN), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -7.97. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is -451.53.

Currently, EBITDA for the company is -43.67 million with net debt to EBITDA at 0.94. When we switch over and look at the enterprise to sales, we see a ratio of 41.85. The receivables turnover for the company is 78.61for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.86.

Conclusion

To sum up, Alpine Immune Sciences Inc (ALPN) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts